Retinal Vein Occlusion occurs when blood flow through a retinal vein becomes blocked causing macular edema, retinal hemorrhages, and decreased vision. Vein occlusions occur in the young as well as elderly population. Until very recently, treatment has been very limited for these conditions.
Current clinical trials for RVO:
There are none at this time.
Past clinical trials for RVO:
A Phase III , multicenter, randomized, sham injection controlled study of the efficacy and safety of Ranibizumab injection compared with sham in subjects with macular edema secondary to Branch retinal vein occlusion.
A Phase III multicenter, randomized sham injection controlled study of the efficacy and safety of Ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion.
Patients enter either Genentech BRAVO or Genentech CRUISE, and then upon completion of either, become a candidate for Genentech HORIZON.
An open label extension study to evaluate the safety and tolerability of Ranibizumab in subjects with RVO who have completed a Genentech sponsored Ranibizumab study.